Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter Randomized Controlled Phase III Study of Nivolumab Alone or in Combination With Ipilimumab as Immunotherapy vs Standard Follow-up in Surgical Resectable HNSCC After Adjuvant Therapy

NCT03700905 is registered in ClinicalTrials.gov with Universitätsklinikum Hamburg-Eppendorf as lead sponsor.

NCT NCT03700905
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03700905 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter Randomized Controlled Phase III Study of Nivolumab Alone or in Combination With Ipilimumab as Immunotherapy vs Standard Follow-up in Surgical Resectable HNSCC After Adjuvant Therapy
Lead sponsor
Universitätsklinikum Hamburg-Eppendorf
Phase
Phase 3
Overall status
Unknown status
Start date
August 21, 2018
Completion date
May 31, 2024
Enrollment
276 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck cancer